N-methyl-3-{4-[3-(4-trifluoromethoxyphenyl)ureido]phenoxy}benzamide | 1394012-09-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-methyl-3-{4-[3-(4-trifluoromethoxyphenyl)ureido]phenoxy}benzamide
• 英文别名: N-methyl-4-[4-[[4-(trifluoromethoxy)phenyl]carbamoylamino]phenoxy]pyridine-2-carboxamide
• CAS: 1394012-09-9
• 化学式: C₂₁H₁₇F₃N₄O₄
• 分子量: 446.386
• InChiKey: OUNLWXRDCKWIDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-氯吡啶-2-甲酰胺 在 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 N-methyl-3-{4-[3-(4-trifluoromethoxyphenyl)ureido]phenoxy}benzamide
  参考文献：
  名称：

  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

  摘要：

  To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.011

文献信息

• SORAFENIB DERIVATIVES AS SEH INHIBITORS
  申请人：Hammock Bruce D.

  公开号：US20140088156A1

  公开（公告）日：2014-03-27

  The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

  本发明提供了用于抑制可溶性环氧酰胺酶及相关疾病状况的化合物。
• Sorafenib derivatives as p21 inhibitors
  申请人：The Regents of the University of California

  公开号：US10449182B2

  公开（公告）日：2019-10-22

  The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.

  本发明提供了用于治疗由p21介导的疾病的方法中的索拉非尼类似物，所述方法包括向有需要的受试者施用治疗有效量的式I化合物。本发明还提供了抑制细胞中p21的方法，包括使细胞与有效量的式I化合物接触。
• SORAFENIB DERIVATIVES AS sEH INHIBITORS
  申请人：The Regents of the University of California

  公开号：EP2675274B1

  公开（公告）日：2017-05-03
• SORAFENIB DERIVATIVES AS P21 INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20150132408A1

  公开（公告）日：2015-05-14

  The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
• US9029401B2
  申请人：——

  公开号：US9029401B2

  公开（公告）日：2015-05-12